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CONCLUSIONS: The prevalence of AF in selected countries was forecasted to grow
substantially in both developing and developed countries. As the world’s popula-
tion ages and health care becomesmore accessible, the economic burden of AFwill
continue to rise as well.
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OBJECTIVES: Estimate the expected number of catheter-related bloodstream infec-
tions (CRBSIs) and the associated costs derived from the adoption of a chlorhexi-
dine-impregnated sponge (Biopatch®) plus central venous catheter (CVC) tradi-
tional standard of care strategy in intensive care units (ICUs) versus CVC traditional
standard of care (no sponge) from a Mexican public hospital perspective.
METHODS: A decision tree was developed to estimate the clinical and economic
consequences of adding Biopatch® to CVC traditional standard of care in adult
population. ICUs’ annual catheter-days were estimated using local average occu-
pancy, number of placed catheters and length of stay published statistics. The
effectiveness variable was the CRBSI rate / 1000 catheter days, obtained from pub-
lished literature and used to estimate annual CRBSIs. It was assumed that once a
patient developed a CRBSI, he incurred in additional length of stay and received the
correspondent pharmacologic treatment; only one infection per patient was al-
lowed. Cost data were obtained from published literature and the public institu-
tion’s price data base; the cost for Biopatch® was internally assessed. The consid-
ered time horizonwas one year, thus no annual discount ratewas used. Costs were
inflation-adjusted and expressed in 2011Mexican pesos. Bivariate sensitivity anal-
yses were performed to assess uncertainty. RESULTS: The addition of Biopatch® to
CVC traditional standard of care in ICUs resulted in a 70% reduction of expected
annual CRBSIs and 0.8% less total costs when compared to the traditional standard
of care alone, thus representing a cost-saving alternative. Results were robust to
25% variations in the price of the sponge, ICU occupancy and CRBSI rates, even in
the extreme scenarios. CONCLUSIONS: The adoption of a Biopatch® plus CVC
traditional standard of care strategy in adult population at ICUs results in signifi-
cant clinical and economic benefits for the hospital, as it reduces CRBSI incidence
and resource utilization.
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OBJECTIVES: Published studies suggest that bypass therapy assay testing can be
used to effectively predict treatment response and dosing requirements for an
individual hemophilia patientwith inhibitors. This study aims to evaluate the costs
and treatment outcomes of bypass therapy assay testing versus no testing strategy
on different treatments for mild to moderate bleeding hemophilia patient with
inhibitors. This study also investigates the cost implications if testing assays could
predict the optimum dose for new type of therapies like concomitant therapy.
METHODS: A decision tree simulation model was used to simulate inhibitor treat-
ment costs and outcomes from a US third party payer perspective. All estimates of
costswere obtained from the literature or expert opinion andwere adjusted to 2011
US dollars. Based on a previous published model, the efficacy of APCC and rFVIIa
were assumed to be the same in the no testing scenario while assay testing was
assumed to improve the efficacy of both the products by 10%. Probabilistic sensi-
tivity analysis was used to determine the robustness of the model’s results. The
model was developed usingMicrosoft Excel and @Risk. RESULTS: If bypass therapy
assay testing successfully predicts the treatment response and improves treat-
ment efficacy by just 10%, cost savings of $6939 for APCC and $7699 for rFVIIa
treatment were observed per bleeding episode. Further, if testing successfully pre-
dicts the optimum dose for concomitant therapy on the onset of bleeding, signifi-
cant cost savings were observed when compared to rFVIIa and APCC therapies
alone. The results were sensitive to frequency of dosing, efficacy, rebleed rate and
drug price. CONCLUSIONS: Bypass therapy assay testing is recommended for re-
ducing costs while optimizing treatment response and dose before administering
treatment in hemophilia patients with inhibitors.
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OBJECTIVES: To compare cost of care among Type II diabetic patients using an
insulin pump delivery system versus alternate methods of insulin delivery (focus
on multiple daily injectors [MDIs]) using administrative claims data. METHODS:
This study used 2009MarketScan®ResearchDatabase data. Patientswere included
if they were continuously enrolled throughout 2009 and were classified as Type II
diabetic based on a combination of diagnosis codes andmedication claimswith the
final application of age where diagnosis was indeterminate. Patients were then
classified as MDIs and insulin pump users based on HCPCS codes and the use of
rapid or short acting insulin prescriptions. Treatment costs were the focus and
included pumps, pump supplies, insulin, and drugs. Costs of complications and
hospitalizations were not included. The study utilized a breakeven analysis to
capture both the fixed and variable costs associated with insulin pumps versus
injection across different cost percentiles of insulin and other drugs. RESULTS: A
total of 68,636 Type II diabetics met inclusion criteria, of which 84% (57,418) were
MDIs, and 16% (11,218) used insulin pumps. Durable insulin pumps required an
upfront investment of approximately $4200 with additional pump supply costs.
Insulin pump users, however, required less insulin and other drugs comparedwith
MDI patients, resulting in less associated costs. Insulin pumps last approximately
four years, and their value proposition increases with the level of insulin use re-
quired. Breakeven analysis revealed patients at the top 10th percentile of expen-
ditures for insulin and other drugs generated savings through lower use of insulin,
which offset the insulin pump cost in 3 years (1,071 days). CONCLUSIONS: Al-
though durable insulin pumps have an upfront cost, they are better able to control
insulin delivery. The reduced drug-related expenditures offset initial pump invest-
ment within three years for the most costly cohort of insulin users.
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OBJECTIVES: To estimate and compare the cost of arthroscopic subacromial de-
compression (SAD) using VAPR®VUE™Radiofrequency Systemwith COOLPULSE®
90 Electrode (COOLPULSE) and the ArthroCare® Quantum™ System with Super
TurboVac® electrode (Super TurboVac).METHODS: An in-vitro study of 72 bovine
tendon specimens was used with COOLPULSE 90 and Super TurboVac. These de-
vices were operated at their default ablation settings (220 and 270Watts for COOL-
PULSE and TurboVac, respectively) for multiple trials. The tissue removal rate was
determined by measuring the tissue mass before and after ablation. The measure
was repeated and averages were calculated. Average length of time needed for
tissue removal in SAD procedures and data on the unit cost of operation room (OR)
time were obtained from clinical model for arthroscopic procedure and published
literature. 2011 IMS data were used to calculate the average selling price for COOL-
PULSE and Super TurboVac. RESULTS: The in-vitro study showed the average ab-
lation rates for COOLPULSE (no clogs were found with COOLPULSE) and Super
TurboVac (excluding data from clogged runs for Super TurboVac) were 1.120.22
gram/minute and 0.930.21 gram/minute, respectively (p  0.001). Average time
for SAD from literature and clinical modeling was 13 minutes and the estimated
cost of OR time in the US was $20/minute. The average costs of ablation using
COOLPULSE and Super TurboVac were estimated to be $436 and $480, respectively.
CONCLUSIONS: Tissue removal rate in arthroscopic procedures is important for
surgical efficiency, for procedure duration that directly benefits patients, and for
cost. The in-vitro study demonstrated that COOLPULSE achieved significantly
higher tissue removal rates compared to Super TurboVac which may result in cost
savings to a surgery facility.
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OBJECTIVES: In December 2011, French health authorities agreed to reimburse the
explantation of defective Poly Implant Prothèse (PIP) breast implants, triggering
responses fromother national policymakers. Spurred by public concern andmedia
coverage, the UK health secretary announced that the National Healthcare Service
(NHS) would remove and replace the defective devices it had installed. Using the
UK as a case study, we evaluated three PIP-related policy scenarios that have been
instituted internationally. A cost comparision model was developed to assess the
cost implications of different explantation scenarios and to identify key cost driv-
ers from the perspective of the NHS.METHODS: The model explored the following
scenarios: (a) immediate removal of all PIP breast implants; (b) targeted removal of
ruptured implants; (c) symptom surveillance, with no extraordinary removal of
implants. Complication (e.g. rupture, silicone leakage) rates were taken from the
medical literature. Event management and screening costs were drawn from NHS
Reference Costs (2009-2010). Sensitivity analyses were conducted using a range of
costs, complication rates and patient numbers. RESULTS: Regardless of observed
rupture rates, reimbursing all explantations was the costliest option, followed by
screening and targeted removal of ruptured implants. Given the apparently low
rate of complications, the least costly optionwas a policy of symptom surveillance,
where explantation stemmed from presentation of rupture-related symptoms.
CONCLUSIONS: The dearth of implant-related complication data makes analysis
of the current crisis challenging. Until reliable data about the clinical implications
of the faulty implants are gathered, policymakerswill struggle to accurately assess
the relative budget impact of their recommendations. Even then, heterogeneity
among the devices exported to different countriesmay confound predictions.More
broadly, the lack of complication data highlighted by this study indicates a need for
improved regulation and monitoring of medical devices to ensure future policy
decisions are better informed.
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